ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS, created in 2005 (United States), from 496 sister brands and 17478 competing brands. The ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS brand is owned by BRISTOL-MYERS SQUIBB COMPANY, a company listed in New York. The sector of ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS is Drug Manufacturers.

ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS is a brand of BRISTOL-MYERS SQUIBB COMPANY (BMY) Sustainability

Here is the evolution of interest in BRISTOL-MYERS SQUIBB COMPANY "sustainability" criteria around the world over the past five years. The graph shows the evolution of the search rate over time, where the value 100 indicates the week with the most searches.
What is the brand's web response on its sustainability: Result of Google's query: "ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS sustainability"
: Sustainability -> Share price